Regulations.gov document
Response Letter from FDA CDER to Bristol Myers Products Inc.
Other · FDA-2022-N-2796 · posted Nov 29, 2022
Key facts
| Document ID | FDA-2022-N-2796-0002 |
|---|---|
| Title | Response Letter from FDA CDER to Bristol Myers Products Inc. |
| Document type | Other |
| Subtype | Response(s) |
| Agency | FDA |
| Docket | FDA-2022-N-2796 |
| Posted | Nov 29, 2022 |
| Comment period opens | Nov 29, 2022 |
At a glance
- None Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: